Form 13G Capricor Therapeutics For: 26 February

An institutional investor filed a Form 13G with the SEC on February 26, 2026, at 07:15 PM regarding ownership in Capricor Therapeutics, a biotechnology company specializing in cardiac and regenerative medicine therapies. The filing indicates passive investment in Capricor Therapeutics exceeding 5% of the company's outstanding shares without intent to influence corporate operations. Form 13G filings are typically submitted by institutional investors, mutual funds, and other large entities that acquire significant stakes in companies without seeking active control. Capricor Therapeutics, headquartered in the United States, has been developing innovative treatments for heart failure and other cardiovascular conditions, with its lead candidate, CAP-1002, showing promise in clinical trials for improving cardiac function in patients with Duchenne muscular dystrophy. The timing of this significant investment filing comes as the biotechnology sector continues to attract substantial capital amid increasing demand for novel cardiovascular treatments and regenerative medicine solutions.